乳腺癌辅助放疗期间TGF-β1与PDGF水平下降与超声心动图改变相关
研究纳入73例接受术后放疗但未化疗的早期乳腺癌或导管原位癌女性,测量放疗前与放疗最后一天血清TGF-β1和PDGF水平并同步行超声心动图。结果显示放疗期间TGF-β1和PDGF均下降,且三尖瓣环收缩期位移(TAPSE)或心包校准积分背散射(cIBS)恶化≥15%的患者基线细胞因子更高、下降幅度更大。
要点
- 放疗期间中位TGF-β1从25.0 ng/ml降至23.6 ng/ml(p=0.003),中位PDGF从18.0 ng/ml降至15.6 ng/ml(p<0.001)。
- TAPSE下降≥15%组基线TGF-β1和PDGF高于下降<15%组,且放疗期间两者均显著下降。
- cIBS增加≥15%组TGF-β1和PDGF均显著下降,而增加<15%组无显著变化。
核心结论
- 乳腺癌辅助放疗期间观察到TGF-β1和PDGF水平下降,超声心动图TAPSE和cIBS的改变与TGF-β1和PDGF更大程度的下降相关。
- 更长的随访将揭示放疗期间观察到的这些变化是否转化为心血管疾病发病率的增加。
研究设计与样本
- 研究纳入73例接受术后放疗但未接受化疗的早期乳腺癌或导管原位癌(DCIS)女性。
- 放疗前和放疗最后一天采集血清,用酶联免疫吸附试验测定TGF-β1和PDGF水平,并在同一时间点行超声心动图。
- 根据三尖瓣环收缩期位移(TAPSE)和心包校准积分背散射(cIBS)恶化≥15%对患者进行分组。
主要发现
- 全部患者中位TGF-β1从25.0(IQR 21.1-30.3)ng/ml降至23.6(IQR 19.6-26.8)ng/ml(p=0.003),中位PDGF从18.0(IQR 13.7-22.7)ng/ml降至15.6(IQR 12.7-19.5)ng/ml(p<0.001)。
- TAPSE下降≥15%组基线TGF-β1为30.7(IQR 26.0-35.9)ng/l,高于TAPSE下降<15%组的23.4(IQR 20.1-27.3)ng/l(p<0.001);基线PDGF在TAPSE下降≥15%组为21.5(IQR 15.7-31.2)ng/l,高于TAPSE下降<15%组的16.9(IQR 13.0-21.2)ng/ml。
- TAPSE下降≥15%组中位TGF-β1降至24.7(IQR 20.0-29.8)ng/ml(p<0.001),中位PDGF降至16.7(IQR 12.9-20.9)ng/ml(p<0.001);TAPSE下降<15%组TGF-β1稳定(p=0.104),但PDGF降至15.1(IQR 12.5-18.6)ng/ml(p=0.005)。
- cIBS增加≥15%组TGF-β1从26.0(IQR 21.7-29.7)ng/ml降至22.5(IQR 16.6-26.7)ng/ml(p<0.001),PDGF从19.8(IQR 14.6-25.9)ng/ml降至15.7(IQR 12.8-20.2)ng/ml(p<0.001);cIBS增加<15%组TGF-β1和PDGF无显著变化(p=0.149和p=0.053)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文结论指出更长的随访时间将揭示放疗期间观察到的这些变化是否转化为心血管疾病发病率的增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiation-induced heart disease is mainly caused by activation of the fibrotic process. Transforming growth factor-beta 1 (TGF-β1) and platelet-derived growth factor (PDGF) are pro-fibrotic mediators. The aim of our study was to evaluate the behavior of TGF-β1 and PDGF during adjuvant radiotherapy (RT) for breast cancer and the association of these cytokines with echocardiographic changes. METHODS: Our study included 73 women with early-stage breast cancer or ductal carcinoma in situ (DCIS) receiving post-operative RT but not chemotherapy. TGF-β1 and PDGF levels in serum samples taken before and on the last day of RT were measured by an enzyme-linked immunosorbent assay. Echocardiography was also performed at same time points. Patients were grouped according to a ≥ 15% worsening in tricuspid annular plane systolic excursion (TAPSE) and pericardium calibrated integrated backscatter (cIBS). RESULTS: In all patients, the median TGF-β1 decreased from 25.0 (IQR 21.1-30.3) ng/ml to 23.6 (IQR 19.6-26.8) ng/ml (p = 0.003), and the median PDGF decreased from 18.0 (IQR 13.7-22.7) ng/ml to 15.6 (IQR 12.7-19.5) ng/ml (p < 0.001). The baseline TGF-β1, 30.7 (IQR 26.0-35.9) ng/l vs. 23.4 (IQR 20.1-27.3) ng/l (p < 0.001), and PDGF, 21.5. (IQR 15.7-31.2) ng/l vs. 16.9. (IQR 13.0-21.2) ng/ml, were higher in patients with a ≥ 15% decrease in TAPSE than in patients with a < 15% decrease. In patients with a ≥ 15% decrease in TAPSE, the median TGF-β1 decreased to 24.7 (IQR 20.0-29.8) ng/ml (p < 0.001), and the median PDGF decreased to 16.7 (IQR 12.9-20.9) ng/ml (p < 0.001). The patients with a < 15% decrease had stable TGF-β1 (p = 0.104), but PDGF decreased to 15.1 (IQR 12.5-18.6), p = 0.005. The patients with a ≥ 15% increase in cIBS exhibited a decrease in TGF-β1 from 26.0 (IQR 21.7-29.7) to 22.5 (IQR 16.6.-26.7) ng/ml, p < 0.001, and a decrease in PDGF from 19.8 (IQR 14.6-25.9) to 15.7 (IQR 12.8-20.2) ng/ml, p < 0.001. In patients with a < 15% increase, TGF-β1 and PDGF did not change significantly, p = 0.149 and p = 0.053, respectively. CONCLUSION: We observed a decrease in TGF-β1 and PDGF levels during adjuvant RT for breast cancer. Echocardiographic changes, namely, in TAPSE and cIBS, were associated with a greater decrease in TGF-β1 and PDGF levels. Longer follow-up times will show whether these changes observed during RT translate into increased cardiovascular morbidity.
引用
- Aula H, Skyttä T, Tuohinen S, et al. Decreases in TGF-β1 and PDGF levels are associated with echocardiographic changes during adjuvant radiotherapy for breast cancer. Radiat Oncol. 2018. PMID: 30340644. doi:10.1186/s13014-018-1150-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。